SOP Guide for Pharma

Analytical Method Development: SOP for Stability-Indicating Method for Lyophilized Injections – V 2.0

Analytical Method Development: SOP for Stability-Indicating Method for Lyophilized Injections – V 2.0

Standard Operating Procedure for Stability-Indicating Method for Lyophilized Injections in Analytical Method Development


Department Analytical Method Development
SOP No. SOP/AMD/277/2025
Supersedes SOP/AMD/277/2022
Page No. Page 1 of 13
Issue Date 21/05/2025
Effective Date 23/05/2025
Review Date 21/05/2026

1. Purpose

To define a validated analytical procedure for the development of a stability-indicating method (SIM) for lyophilized injectable formulations, capable of distinguishing the active pharmaceutical ingredient (API)

from its degradation products under forced degradation and stability conditions.

2. Scope

This SOP applies to Analytical Method Development and Quality Control departments responsible for establishing and validating stability-indicating methods for lyophilized injections as part of regulatory submissions and ongoing stability programs.

3. Responsibilities

  • Analytical Scientist: Develops and validates the method, performs forced degradation, and interprets results.
  • Stability Team: Provides samples from various storage conditions for method evaluation.
  • QA Executive: Reviews method development protocol and ensures regulatory compliance.

4. Accountability

The Head of Analytical Method Development is accountable for the suitability, validation, and regulatory acceptance of the SIM developed for lyophilized injectable products.

5. Procedure

5.1 Selection of Analytical Technique

  1. HPLC with UV detection is preferred; other options include HPLC-MS or UPLC depending on sensitivity and regulatory requirement.
  2. Select detection wavelength based on UV spectrum of API and degradation products.

5.2 Forced Degradation Studies

  1. Subject the API and lyophilized formulation to stress conditions:
    • Acid hydrolysis (0.1N HCl, 2 hours at 60°C)
    • Alkali hydrolysis (0.1N NaOH, 2 hours at 60°C)
    • Oxidation (3% H2O2, 2 hours at 25°C)
    • Thermal stress (80°C for 24 hours)
    • Photolysis (UV exposure for 24 hours)
  2. Neutralize samples if needed and analyze using preliminary method.

5.3 Method Optimization

  1. Optimize chromatographic conditions to achieve baseline separation of API from all degradation products.
  2. Adjust mobile phase pH, gradient, temperature, and column type (e.g., C18).

5.4 Sample and Standard Preparation

  1. Reconstitute lyophilized powder using sterile WFI as per product instructions.
  2. Prepare standard solution of API at known concentration in diluent.
  3. Filter through 0.22 µm membrane before injection.

5.5 HPLC Conditions (Typical)

  • Column: C18, 250 mm × 4.6 mm, 5 µm
  • Mobile Phase: Water (pH 3.0 with OPA):Acetonitrile = 65:35 v/v
  • Flow Rate: 1.0 mL/min
  • Detection: 230 nm
  • Injection Volume: 20 µL

5.6 Validation Parameters

  1. Specificity: Degradation peaks must be well resolved from API with purity angle < purity threshold.
  2. Linearity: r² ≥ 0.999 across 50%–150% of target concentration.
  3. Accuracy: 98%–102% recovery at 3 concentration levels.
  4. Precision: RSD ≤ 2.0% for repeatability and intermediate precision.
  5. LOD/LOQ: Established for API and major degradation products.
  6. Robustness: Minor changes in pH, flow rate, and temperature should not affect resolution.

5.7 Acceptance Criteria

  • API peak should be separated with resolution ≥ 2.0 from nearest impurity.
  • No co-elution with excipients or degradation peaks.
  • Peak purity index ≥ 0.999.

6. Abbreviations

  • SIM: Stability Indicating Method
  • HPLC: High Performance Liquid Chromatography
  • LOD: Limit of Detection
  • LOQ: Limit of Quantification
  • WFI: Water for Injection

7. Documents

  1. Stability-Indicating Method Development Log – Annexure-1
  2. Forced Degradation Summary Table – Annexure-2
  3. Validation Report – Annexure-3

8. References

  • ICH Q2(R1): Validation of Analytical Procedures
  • ICH Q1A(R2): Stability Testing of New Drug Substances and Products
  • USP <621>, <1225>, <1086>

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name Anita Kulshreshtha Ravi Iyer Sunita Reddy
Designation Stability Chemist QA Reviewer Head – AMD
Department Analytical Method Development QA Analytical Method Development

11. Annexures

Annexure-1: Stability-Indicating Method Development Log

Sample ID Stress Condition Degradation (%) Resolution Status
SIM-277-01 Acid hydrolysis 15% 3.5 Pass

Annexure-2: Forced Degradation Summary Table

Condition Duration Degradation Observed Comments
0.1N NaOH 2 hr @ 60°C 18% Major degradation at 2.8 min

Annexure-3: Validation Report

The developed SIM was validated for a lyophilized cephalosporin formulation. It effectively resolved degradants from API and met all ICH validation criteria. The method is suitable for long-term and accelerated stability studies.

Revision History:

Revision Date Revision No. Details Reason Approved By
21/05/2025 2.0 Included Annexure for degradation summary, expanded robustness Annual Review Sunita Reddy
01/05/2022 1.0 Initial Release New SOP QA Head
Exit mobile version